• E W Ehrich, J A Bolognese, D J Watson, and S X Kong.
• Merck & Co Inc, One Merck Drive (WS1B-75), Whitehouse Station, NJ 08889, USA.
• Am J Manag Care. 2001 Jun 1; 7 (6): 609616609-16.

BackgroundBodily pain and physical disability can negatively impact health-related quality of life (HRQL) in patients with osteoarthritis (OA).ObjectiveTo assess the effects of treatment with a new agent, rofecoxib, on HRQL in patients with OA.Study DesignRandomized, double-blind, 6-week clinical trial comparing treatment with rofecoxib, 5 to 50 mg, with placebo in 672 patients with OA of the hip or knee.Main Outcome MeasurePatient HRQL was assessed at baseline and at the end of treatment using the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36).ResultsAt 6 weeks, mean change from baseline in all SF-36 mental and physical health domain scores demonstrated significant improvement with rofecoxib use (P < .05 for all doses for all SF-36 domains), with evidence of a dose-response relation. Improvements in mental and physical HRQL domains with rofecoxib treatment were significantly greater than those with placebo treatment (P < .05 for each dose of rofecoxib vs placebo for all domains except general health) and highly correlated with improvements observed using disease-specific OA outcome measures such as the Western Ontario and McMaster Universities Osteoarthritis Index-visual Analog 3.0 OA index pain and physical function subscales. The effect of rofecoxib vs placebo treatment on mental health largely disappeared after adjustment for improvement in OA disease-specific measures.ConclusionsRofecoxib treatment increased physical and mental HRQL domain scores on the SF-36. Improvements in mental health with rofecoxib use primarily resulted from effective treatment of OA (i.e., reduction in pain and improvement in physical function).

19 keywords...

hide…